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General Considerations  
 
 
(A) General Analytical Information. 
  Nuclear Magnetic Resonance spectra were recorded on a Bruker Avance 400 MHz instruments at 
ambient temperature. All 
1
H NMR spectra were measured in part per million (ppm) relative to the signal 
of tetramethylsilane (TMS) added into the deuterated chloroform (CDCl3, 0.00 ppm), the signal of 
residual dichloromethane in deuterated dichloromethane (CD2Cl2, 5.32 ppm), or the signal of residual 
dimethyl sufloxide in dimethyl-d6 sufloxide (DMSO-d6, 2.50 ppm).
1
 Data for 
1
H NMR were reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qu = quintet, sex = 
sextet, m = multiplet, ovrlp = overlap, br = broad), coupling constants, and integration. All 
13
C NMR 
spectra were reported in ppm relative to CDCl3 (77.16 ppm), CD2Cl2 (53.84 ppm), or DMSO-d6 (39.52 
ppm)
1
 and were obtained with complete 
1
H decoupling. All 
19
F NMR spectra were reported in ppm 
relative to hexafluorobenzene as an internal standard (-164.9 ppm, with reference to CFCl3 at 0 ppm) and 
were obtained with complete 
1
H decoupling. All gas chromatography (GC) analyses were performed on a 
Perkin-Elmer Clarus 400 GC system with a FID detector. All gas chromatography-mass spectrometry 
(GC-MS) analyses were performed on an Agilent Technologies 7890A GC system equipped with a 
5975C MS detector. High-resolution mass spectra (HRMS) by electrospray ionization (ESI) method were 
performed at the EPFL ISIC Mass Spectroscopy Service with a Micro Mass QTOF Ultima spectrometer. 
Intra-red (IR) spectra were recorded on solid or liquid samples on a Varian 800 FT-IR spectrometer using 
attenuated total reflectance (ATR) sampling techniques. Melting points (Mp) of solid compounds were 
measured using Büchi Model B-540 melting point apparatus.   
 
 
(B) General Reagent Information. 
  Unless otherwise noted, all chemicals were used as received without further purifications. Anhydrous 
N-methylpyrrolidone (NMP) (99.8% purity, in Sure-Seal bottle), zinc powder (Zn, >98% purity), 
manganese powder (Mn, 99.99% purity), and chlorotrimethylsilane (TMSCl, ≥98% purity) were 
purchased from Aldrich Chemical Co.. Nickel(II) chloride ethylene glycol dimethyl ether complex 
(Ni(glyme)Cl2) was purchased from ABCR GmbH& Co. KG. 1,10-Phenanthroline (phen) was purchased 
from Acros Chemicals. Iodotrimethylsilane (TMSI, ≥95% purity), 2,2′:6′,2′′-terpyridine (terpyridine), and 
4,7-dimethyl-1,10-phenanthroline were purchased from TCI Chemicals. While low molecular weight 
organic compounds containing multiple nitro groups are potentially explosive, the nitroarenes used in this 
study contain only one nitro group and we encountered no safety issues in their preparation and uses. The 
following known starting materials (amides and nitroarenes) were prepared according to the literature 
procedures:
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(C) General Manipulation Considerations.    
   
  All manipulations for the nickel-catalyzed reductive transamidation with nitroarenes were set up in a 30 
mL Teflon-screw capped test tubes under an inert nitrogen (N2) atmosphere using glove-box techniques. 
The test tubes were then sealed with airtight electrical tapes and the reaction mixtures were stirred in a 
preheated oil-bath. Flash column chromatography was performed using silica gel (Silicycle, ultra pure 
grade). Preparative thin-layer chromatography (preparative TLC) was performed using preparative TLC 
plate (Merck Millipore, TLC Silica gel 60 F254, 20 x 20 cm, catalogue number: 1.05715.0001) in a 
developing tank. Notably, the TLC plates used for the purification of amide products were washed with 
hexanes/triethylamine solution (volume ratio ~20:1) prior to use in order to minimize the product loss. 
The eluents for column chromatography and preparative TLC were presented as ratios of solvent 
volumes. Yields reported in the publication are of isolated materials unless otherwise noted. All new 
starting materials and amide products were characterized by 
1
H and 
13
C NMR spectroscopies, high-
resolution mass spectrometry (HRMS), infra-red (IR) spectroscopy, and melting point (Mp) measurement 
(for soild compounds). All known amide products were characterized by 
1
H and 
13
C NMR spectroscopies 
(the spectra were compared with the reported data if provided), and most of them were further 
characterized by infra-red spectroscopy.  
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Supplementary Data 
 
 
 
(A) Optimization of Reaction Conditions for Nickel-Catalyzed Reductive 
Transamidation of Alkyl Amide with Nitrobenzene. 
 
  Boc-activated secondary alkyl amide, tert-butyl benzyl(decanoyl)carbamate (1a), and nitrobenzene 
(PhNO2, 2a) were used as the model substrates of alkyl amide and nitroarene, respectively. After the 
screening of reaction parameters, we found that the reductive coupling of 1a with 2a proceeded 
smoothly at 100 
o
C to yield the desired amide product, N-phenyl decanamide, in 80% yield in the 
presence of Zn reductant (5 equiv), TMSCl additive (2 equiv), NMP solvent (0.5 M of 1a), and 
Ni(glyme)Cl2 (10 mol %)/phen (10 mol %) as the catalyst system (Table S1, entry 1). The use of other 
ligands (Table S1, entries 2-9), nickel catalysts (Table S1, entries 10-13), additives (Table S1, entries 
16-19), reductant (Mn, Table S1, entry 22), and solvents (Table S1, entries 26 and 27) led to 
diminishment in yields. The variation of loadings of Ni(glyme)Cl2 (Table S1, entries 14 and 15), 
TMSCl (Table S1, entries 20 and 21), Zn (Table S1, entries 23-25), and 2a (Table S1, entries 29 and 
30), as well as the change in solvent volume (Table S1, entry 28) or reaction temperatures (Table S1, 
entries 31 and 32), also resulted in drop of yields. The use of other transition metal catalysts (Fe, Co, 
Cu. Mn) resulted in much lower yields of product (Table S1, entries 33-36). Control experiments 
demonstrated that TMSCl, Ni(glyme)Cl2 catalyst, and phen ligands were essential to promote the 
reductive transmidation (Table S1, entries 37-40). The reaction with aniline only gave a low yield of 
amide (Table S1, entries 41 and 42), suggesting that aniline is unlikely the active intermediate in 
transamidation.  
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Table S1. Optimizations of Nickel-Catalyzed Reductive Transamidation of Boc-activated Secondary 
Alkyl Amide with Nitrobenzene  
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(B) Optimization of Reaction Conditions for Nickel-Catalyzed Reductive 
Transamidation of Aryl Amide with Nitrobenzene. 
 
  Boc-activated secondary aryl amide, tert-butyl benzoyl(benzyl)carbamate (1b), and nitrobenzene (2a) 
were used as the model substrates of aryl amide and nitroarene, respectively. Initially, we applied the 
optimal conditions in Table S1 (Table S1, entry 1) for the reactions, and the desired product, N-phenyl 
benzamide, was obtained in 63% yield (Table S2, entry 1). After the subsequent screening of reaction 
parameters, we found that the reductive coupling of 1b with 2a proceeded smoothly at 80 
o
C to yield 
N-phenyl benzamide in 88% yield in the presence of Mn reductant (5 equiv), TMSI additive (1 equiv), 
NMP solvent (0.5 M of 1b), and Ni(glyme)Cl2 (10 mol %)/terpyridine (10 mol %) as the catalyst 
system (Table S2, entry 2). The use of other ligands (Table S2, entries 3-10), nickel catalysts (Table 
S2, entries 11 and 12), additives (Table S2, entries 15-17), reductant (Zn, Table S2, entry 20), and 
solvent (Table S2, entry 23) led to diminishment in yields. The variation of loadings of Ni(glyme)Cl2 
(Table S2, entries 13 and 14), TMSI (Table S2, entries 18 and 19), Mn (Table S2, entries 21 and 22), 
and 2a (Table S2, entries 25 and 26), as well as the change in solvent volume (Table S2, entry 24) or 
reaction temperatures (Table S2, entries 27 and 28), also resulted in drop of yields. The use of other 
transition metal catalysts (Fe, Co, Cu. Mn) resulted in modest product yields (Table S2, entries 29-32). 
Control experiments demonstrated that TMSI, Ni(glyme)Cl2 catalyst, and terpyridine ligand were 
essential to promote the reductive transmidation (Table S2, entries 33-36). The reaction with aniline 
only gave a low yield of amide (Table S2, entry 37), suggesting that aniline is unlikely the active 
intermediate in transamidation.  
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Table S2. Optimizations of Nickel-Catalyzed Reductive Transamidation of Boc-activated Secondary 
Aryl Amide with Nitrobenzene  
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Experimental Section  
 
 
 
Synthesis of Starting Materials:  
 
 
 
General Procedures for the Synthesis of Boc-Activated Secondary Amides (General Procedure 
A).  
  Step 1: An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar 
was sequentially charged with dichloromethane solvent (CH2Cl2), amide, and triethylamine (Et3N). 
The reaction mixture was stirred at room temperature, and acyl chloride was slowly added in a few 
portions into the reaction mixture. The resulting mixture was stirred at room temperature overnight. 
After the reaction, the organic fraction was washed with dilute HCl solution (~1 M, ~100 mL), 
followed by saturated NaOH solution (~30 mL), and finally saturated NaCl solution (~50 mL). The 
organic fraction was dried with MgSO4 powder and then dried in vacuo with the aid of a rotary 
evaporator to obtain the residue as a secondary amide.  
  Step 2: All secondary amide prepared from step 1 was transferred into an oven-dried 500 mL round-
bottom flask equipped with a Teflon-coated magnetic stir bar, and acetonitrile solvent (MeCN), 4-
(N,N-dimethylamino)pyridine (DMAP, 10 mol %), and di-tert-butyl dicarbonate (Boc2O) were then 
added. The resulting mixture was stirred at room temperature overnight. After the reaction, the 
reaction mixture was dried in vacuo, and the crude product was washed with ethyl acetate (EtOAc, 
~100 mL) and dilute HCl solution (~1 M, ~100 mL). The organic fraction was further washed with 
saturated NaHCO3 solution (~100 mL) followed by saturated NaCl solution (~50 mL). The organic 
fraction was then concentrated in vacuo, and the residue was purified by flash chromatography with 
silica gel (without prior washing with Et3N/hexanes) using a mixture of hexanes/EtOAc as an eluent to 
afford the activated, Boc-activated secondary amide.  
 
 
 
tert-Butyl Benzyl(4-(tert-butyl)benzoyl)carbamate (S1). Following the general procedure A, the title 
compound was prepared by (i) using 4-tert-butylbenzoyl chloride (1 equiv, 1.2 mL, 6.0 mmol), 
benzylamine (1.2 equiv, 7.2 mmol, 0.77 mL), Et3N (1.5 equiv, 9 mmol, 1.23 mL), and CH2Cl2 (100 
mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 1.4 mL), DMAP (73 
mg), and MeCN (100 mL) to prepare activated amide. The crude product was purified using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (1.39 
g, 63%). 
1
H NMR (400 MHz, CD2Cl2): δ 7.50-7.44 (ovrlp, 4 H), 7.42 (d, J = 7.6 Hz, 2 H), 7.35 (t, J = 
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7.6 Hz, 2 H), 7.28 (t, J = 7.3 Hz, 1 H), 4.97 (s, 2 H), 1.35 (s, 9 H), 1.14 (s, 9 H). 
13
C NMR (100 MHz, 
CD2Cl2): δ 173.4, 155.2, 153.9, 138.7, 135.3, 128.8, 128.2, 127.8, 127.6, 125.4, 83.3, 49.2, 35.3, 31.3, 
27.5. HRMS (ESI): Calcd for C23H29NO3Na [M+Na]: 390.2045; Found: 390.2045. IR (neat, cm
-1
): 
1716, 1681, 1359, 1235, 1152, 970, 850. Mp: 66-68 
o
C. 
 
 
 
tert-Butyl Benzoyl(propyl)carbamate (S2). Following the general procedure A, the title compound 
was prepared by (i) using benzoyl chloride (1 equiv, 1.2 mL, 10 mmol), n-propylamine (1.2 equiv, 12 
mmol, 0.99 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) to prepare the secondary 
amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), DMAP (122 mg), and MeCN (150 mL) to 
prepare the activated amide. The crude product was purified using hexanes/EtOAc (10:1) as an eluent 
to afford the title compound as a yellow liquid (855 mg, 32%). 
1
H NMR (400 MHz, CD2Cl2): δ 7.53-
7.46 (ovrlp, 3 H), 7.41 (t, J = 7.6 Hz, 2 H), 3.77 (t, J = 7.3 Hz, 2 H), 1.73 (hex, J = 7.4 Hz, 2 H), 1.17 
(s, 9 H), 0.99 (t, J = 7.4 Hz, 3 H). 
13
C NMR (100 MHz, CD2Cl2): δ 173.4, 153.9, 138.8, 131.1, 128.4, 
127.7, 82.9, 47.6, 27.5, 22.5, 11.6. HRMS (ESI): Calcd for C15H21NO3Na [M+Na]: 286.1419; Found: 
286.1426. IR (neat, cm
-1
): 1729, 1669, 1336, 1233, 1139, 1071.  
 
 
 
tert-Butyl Benzoyl(hexyl)carbamate (S3). Following the general procedure A, the title compound 
was prepared by (i) using benzoyl chloride (1 equiv, 1.2 mL, 10 mmol), n-hexylamine (1.2 equiv, 12 
mmol, 1.6 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) to prepare the secondary 
amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), DMAP (122 mg), and MeCN (150 mL) to 
prepare the activated amide. The crude product was purified using hexanes/EtOAc (10:1) as an eluent 
to afford the title compound as a yellow liquid (1.48 g, 48 %). 
1
H NMR (400 MHz, CD2Cl2): δ 7.50 
(d, J = 7.7 Hz, 2 H), 7.45 (t, J = 7.9 Hz, 1 H), 7.37 (t, J = 7.1 Hz, 2 H), 3.80 (t, J = 7.7 Hz, 2 H), 1.69 
(qu, J = 6.9 Hz, 2 H), 1.40-1.27 (ovrlp, 6 H), 1.14 (s, 9 H), 0.89 (t, J = 6.3 Hz, 3 H). 
13
C NMR (100 
MHz, CD2Cl2): δ 173.1, 153.5, 138.2, 130.7, 127.9, 127.2, 82.6, 45.7, 31.4, 28.7, 27.3, 26.5, 22.5, 
14.0. HRMS (ESI): Calcd for C18H27NO3Na [M+Na]: 328.1889; Found: 328.1879. IR (neat, cm
-1
): 
1729, 1671, 1337, 1138.  
 
 
 
tert-Butyl Isobutyl(4-(trifluoromethyl)benzoyl)carbamate (S4). Following the general procedure A, 
the title compound was prepared by (i) using 4-(trifluoromethy)benzoyl chloride (1 equiv, 12 mmol, 
1.79 mL), isobutylamine (1.3 equiv, 15.6 mmol, 1.55 mL), Et3N (1.5 equiv, 18 mmol, 2.5 mL), and 
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CH2Cl2 (200 mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.9 mL), 
DMAP (146 mg), and MeCN (200 mL) to prepare the activated amide. The crude product was purified 
using hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid 
(3.31 g, 80 %). 
1
H NMR (400 MHz, CD2Cl2): δ 7.70 (d, J = 8.2 Hz, 2 H), 7.63 (d, J = 8.1 Hz, 2 H), 
3.68 (d, J = 7.3 Hz, 2 H), 2.20-2.06 (m, 1 H), 1.19 (s, 9 H), 0.98 (d, J = 6.7 Hz, 6 H). 
13
C NMR (100 
MHz, CD2Cl2): δ 172.2, 153.9, 142.5, 132.6 (q, 
2
JCF = 32.3 Hz), 128.0, 125.6 (q, 
3
JCF = 15.1 Hz), 
124.5 (q, 
1
JCF = 270.5 Hz), 83.8, 32.9, 28.7, 27.6, 20.5. 
19
F NMR (376 MHz, CDCl3): δ -66.0. HRMS 
(ESI): Calcd for C17H22F3NO3Na [M+Na]: 368.1450; Found: 368.1448. IR (neat, cm
-1
): 1737, 1658, 
1327, 1237, 1169, 1107, 862, 763. Mp: 56-58 
o
C. 
 
 
 
tert-Butyl Decanoyl(methyl)carbamate (S5). Following the general procedure A, the title compound 
was prepared by (i) using decanoyl chloride (1 equiv, 20 mmol, 4.2 mL), methylamine (2 M solution 
in THF, 2 equiv, 40 mmol, 20 mL), Et3N (1.5 equiv, 30 mmol, 4.2 mL), and CH2Cl2 (250 mL) to 
prepare the secondary amide, followed by (ii) using Boc2O (1.3 equiv, 5.7 mL), DMAP (244 mg), and 
MeCN (250 mL) to prepare the activated amide. The crude product was purified using hexanes/EtOAc 
(10:1) as an eluent to afford the title compound as a pale-brown liquid (3.78 g, 66%). 
1
H NMR (400 
MHz, CDCl3): δ 3.13 (s, 3 H), 2.84 (t. J = 7.7 Hz, 2 H), 1.63 (qu. J = 7.1 Hz, 2 H), 1.53 (s, 9 H), 1.37-
1.20 (ovrlp, 12 H), 0.88 (t. J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 176.4, 153.5, 82.8, 38.4, 
32.0, 31.5, 29.6, 29.38, 29.37, 28.1, 25.3, 22.8, 14.2 (13 of 14 carbons observed). HRMS (ESI): Calcd 
for C16H31NO3Na [M+Na]: 308.2202; Found: 308.2192. IR (neat, cm
-1
): 1733, 1699, 1314, 1143.  
 
 
 
 
tert-Butyl Benzyl(undec-10-enoyl)carbamate (S6). Following the general procedure A, the title 
compound was prepared by (i) using undec-10-enoyl chloride (1 equiv, 12 mmol, 2.6 mL), 
benzylamine (1.2 equiv, 14.4 mmol, 1.54 mL), Et3N (1.5 equiv, 18 mmol, 2.5 mL), and CH2Cl2 (150 
mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.9 mL), DMAP (146 
mg), and MeCN (150 mL) to prepare the activated amide. The crude product was purified using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as a yellow liquid (3.18 g, 71%). 
1
H 
NMR (400 MHz, CD2Cl2): δ 7.32 (t. J = 7.4 Hz, 2 H), 7.28-7.23 (ovrlp, 3 H), 5.91-5.81 (m, 1 H), 
5.06-5.00 (m, 1 H), 4.98-4.94 (m, 1 H), 4.90 (s, 2 H), 2.92 (t. J = 7.7 Hz, 2 H), 2.08 (q. J = 7.4 Hz, 2 
H), 1.68 (qu. J = 7.2 Hz, 2 H), 1.44 (s, 9 H), 1.39-1.31 (ovrlp, 10 H). 
13
C NMR (100 MHz, CD2Cl2): δ 
176.4, 153.6, 139.7, 139.3, 128.7, 127.8, 127.4, 114.4, 83.4, 47.7, 38.7, 34.3, 29.92, 29.86, 29.8, 29.6, 
29.5, 28.1, 25.8. HRMS (ESI): Calcd for C23H35NO3Na [M+Na]: 396.2515; Found: 396.2519. IR 
(neat, cm
-1
):  1733, 1697, 1368, 1146, 630.  
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tert-Butyl Decanoyl(phenethyl)carbamate (S7). Following the general procedure A, the title 
compound was prepared by (i) using decanoyl chloride (1 equiv, 10 mmol, 2.1 mL), 2-phenylethan-1-
amine (1.2 equiv, 12 mmol, 1.5 mL), Et3N (1.5 equiv, 15 mmol, 2.l mL), and CH2Cl2 (200 mL) to 
prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), DMAP (122 mg), and 
MeCN (250 mL) to prepare the activated amide. The crude product was purified using hexanes/EtOAc 
(10:1) as an eluent to afford the title compound as a pale-brown liquid (1.23 g, 33%). 
1
H NMR (400 
MHz, CDCl3): δ 7.26 (d, J = 6.6 Hz, 2 H), 7.21-7.17 (ovrlp, 3 H), 3.88 (t, J = 7.8 Hz, 2 H), 2.85-2.79 
(ovrlp, 4 H), 1.62 (qu, J = 7.2 Hz, 2 H), 1.48 (s, 9 H), 1.34-1.23 (ovrlp, 12 H), 0.88 (t, J = 7.0 Hz, 3 
H). 
13
C NMR (100 MHz, CDCl3): δ 176.1, 153.1, 139.0, 129.0, 128.5, 126.4, 82.7, 46.1, 38.5, 35.1, 
32.0, 29.6, 29.5, 29.4, 29.3, 28.0, 25.2, 22.7, 14.2. HRMS (ESI): Calcd for C23H37NO3 Na [M+Na]: 
398.2671; Found: 398.2668. IR (neat, cm
-1
): 1732, 1695, 1368, 1143.  
 
 
 
 
tert-Butyl (Cyclopropylmethyl)(decanoyl)carbamate (S8). Following the general procedure A, the 
title compound was prepared by (i) using decanoyl chloride (1 equiv, 10 mmol, 2.1 mL), 
cyclopropylmethanamine (1.2 equiv, 12 mmol, 1.13 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and 
CH2Cl2 (200 mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), 
DMAP (121 mg), and MeCN (250 mL) to prepare the activated amide. The crude product was purified 
using hexanes/EtOAc (10:1) as an eluent to afford the title compound as a brown liquid (1.43 g, 44%). 
1
H NMR (400 MHz, CDCl3): δ 3.50 (d, J = 7.0 Hz, 2 H), 2.76 (t, J = 7.6 Hz, 2 H), 1.55 (qu, J = 6.8 
Hz, 2 H), 1.46 (s, 9 H), 1.30-1.14 (ovrlp, 12 H), 1.08-0.97 (m, 1 H), 0.80 (t, J = 6.7 Hz, 3 H), 0.38-.31 
(m, 2 H), 0.25-0.19 (m, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 176.4, 153.6, 82.6, 48.6, 38.6, 32.0, 
29.6, 29.38, 29.37, 28.1, 25.4, 22.8, 14.2, 10.7, 3.6 (15 of 16 carbons observed). HRMS (ESI): Calcd 
for C19H35NO3Na [M+Na]: 348.2515; Found: 348.2508. IR (neat, cm
-1
): 1730, 1697, 1368, 1246, 
1141.  
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tert-Butyl Decanoyl(2-methoxyethyl)carbamate (S9). Following the general procedure A, the title 
compound was prepared by (i) using decanoyl chloride (1 equiv, 10 mmol, 2.1 mL), 2-methoxyethan-
1-amine (1.2 equiv, 12 mmol. 1.05 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (200 mL) to 
prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), DMAP (121 mg), and 
MeCN (250 mL) to prepare the activated amide. The crude product was purified using hexanes/EtOAc 
(10:1) as an eluent to afford the title compound as a pale-brown liquid (1.31 g, 40%). 
1
H NMR (400 
MHz, CDCl3): δ 3.90 (t, J = 6.0 Hz, 2 H), 3.47 (t, J = 6.0 Hz, 2 H), 3.33 (s, 3 H), 2.82 (t, J = 7.4 Hz, 2 
H), 1.62 (qu, J = 7.0 Hz, 2 H), 1.53 (s, 9 H), 1.34-1.23 (ovrlp, 12 H), 0.88 (t, J = 7.0 Hz, 2 H). 
13
C 
NMR (100 MHz, CDCl3): δ 176.1, 153.3, 82.9, 70.5, 58.7, 43.4, 38.3, 31.9, 29.5, 29.33, 29.30, 28.0, 
25.3, 22.7, 14.1 (15 of 16 carbons observed). HRMS (ESI): Calcd for C18H35NO4Na [M+H]: 
352.2464; Found: 352.2465. IR (neat, cm
-1
): 1733, 1693, 1368, 1350, 1143, 1121, 1077.  
 
 
 
 
tert-Butyl Decanoyl(3-(methylthio)propyl)carbamate (S10). Following the general procedure A, the 
title compound was prepared by (i) using decanoyl chloride (1 equiv, 10 mmol, 2.1 mL), 3-
(methylthio)propan-1-amine (1.2 equiv, 12 mmol, 1.42 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and 
CH2Cl2 (200 mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.3 equiv, 2.4 mL), 
DMAP (121 mg), and MeCN (250 mL) to prepare the activated amide. The crude product was purified 
using hexanes/EtOAc (10:1) as an eluent to afford the title compound as a pale-brown, low-melting 
solid (900 mg, 25%). 
1
H NMR (400 MHz, CDCl3): δ 3.69 (t, J = 7.1 Hz, 2 H), 2.75 (t, J = 7.4 Hz, 2 
H), 2.44 (br s, 2 H), 2.05 (br s, 3 H), 1.75 (qu, J = 7.0 Hz, 2 H), 1.54 (t, J = 7.2 Hz, 2 H), 1.46 (s, 9 H), 
1.29-1.14 (ovrlp, 12 H), 0.80 (t, J = 6.7 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 176.2, 153.3, 82.9, 
43.8, 38.5, 32.0, 31.6, 29.6, 29.4, 28.24, 28.16, 25.3, 22.8, 15.4, 14.2 (15 of 17 carbons observed). 
HRMS (ESI): Calcd for C19H37NO3SNa [M+Na]: 382.2392; Found: 382.2396. IR (neat, cm
-1
): 1732, 
1695, 1368, 1253, 1142.  
 
 
 
 
tert-Butyl Decanoyl(2,2,2-trifluoroethyl)carbamate (S11). Following the general procedure A, the 
title compound was prepared by (i) using decanoyl chloride (1 equiv, 10 mmol, 2.1 mL), 2,2,2-
trifluoroethan-1-amine (1.2 equiv, 12 mmol, 0.96 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and 
CH2Cl2 (200 mL) to prepare the secondary amide, followed by (ii) using Boc2O (1.1 equiv, 2.4 mL), 
DMAP (121 mg), and MeCN (250 mL) to prepare the activated amide. The crude product was purified 
using hexanes/EtOAc (10:1) as an eluent to afford the title compound as a colorless liquid (2.53 g, 
72%). 
1
H NMR (400 MHz, CDCl3): δ 4.35 (q, 
3
JCF = 8.6 Hz, 2 H), 2.82 (t, J = 7.6 Hz, 2 H), 1.57 (qu, 
J = 7.0 Hz, 2 H), 1.46 (s, 9 H), 1.28-1.15 (ovrlp, 12 H), 0.80 (t, J = 6.6 Hz, 3 H). 
13
C NMR (100 MHz, 
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CDCl3): δ 175.4, 151.9, 124.1 (q, 
1
JCF = 278.4 Hz), 84.4, 44.2 (q, 
2
JCF = 34.8 Hz), 38.1, 32.0, 29.6, 
29.5, 29.4, 29.2, 27.8, 25.1, 22.8, 14.1. 
19
F NMR (376 MHz, CDCl3): δ -73.2. HRMS (ESI): Calcd for 
C17H30F3NO3Na [M+Na]: 376.2076; Found: 376.2077. IR (neat, cm
-1
): 1746, 1710, 1351, 1252, 1144, 
1092, 628.  
 
 
 
 
Synthesis of tert-Butyl Benzyl(6-chlorohexanoyl)carbamate (12). 
 
  Step 1: An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar 
was sequentially charged with dimethylformamide solvent (DMF, 250 mL), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl, 1.1 equiv, 14.3 mmol, 2.78 g), 1-hydroxybenzotriazole 
hydrate (HOBt.H2O, 1.1 equiv, 14.3 mmol, 2.18 g), triethylamine (Et3N, 1.1 equiv, 14.3 mmol, 2.0 
mL), benzylamine (1 equiv, 13 mmol, 1.39 g), and 6-chlorohexanoic acid (1 equiv, 13 mmol, 1.96 g). 
The reaction mixture was stirred at room temperature overnight. After the reaction, the reaction 
mixture was washed with water (~500 mL) and ethyl acetate (EtOAc, ~100 mL). The organic fraction 
was further washed with dilute HCl solution (~1 M, ~100 mL), followed by saturated NaOH solution 
(~30 mL), and finally saturated NaCl solution (~50 mL). The organic fraction was dried with MgSO4 
powder and then dried in vacuo with the aid of a rotary evaporator to obtain the residue as a secondary 
amide, N-benzyl-6-chlorohexanamide.  
  Step 2: All N-benzyl-6-chlorohexanamide prepared from step 1 was transferred into an oven-dried 
500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar, and acetonitrile solvent 
(MeCN, 100 mL), 4-(N,N-dimethylamino)pyridine (DMAP, 10 mol %, 158 mg), and di-tert-butyl 
dicarbonate (Boc2O, 1.1 equiv, 3.l mL) were then added. The resulting mixture was stirred at room 
temperature overnight. After the reaction, the reaction mixture was concentrated in vacuo, and the 
crude product was washed with EtOAc, ~100 mL) and dilute HCl solution (~1 M, ~100 mL). The 
organic fraction was further washed with saturated NaHCO3 solution (~50 mL) followed by saturated 
NaCl solution (~100 mL). The organic fraction was dried and concentrated in vacuo, and the residue 
was purified by flash chromatography with silica gel (without prior washing with Et3N/hexanes) using 
a mixture of hexanes/EtOAc (10:1) as an eluent to afford the title compound as a pale-yellow liquid 
(1.74 g, 39%).  
  
1
H NMR (400 MHz, CD2Cl2): δ 7.36-7.24 (ovrlp, 5 H), 4.92 (s, 2 H), 3.57 (t, J = 5.2 Hz, 2 H), 2.96 
(t, J = 5.4 Hz, 2 H), 1.83 (qu, J = 5.5 Hz, 2 H), 1.72 (qu, J = 6.2 Hz, 2 H), 1.56-1.50 ((m, 2 H), 1.45 (s, 
9 H). 
13
C NMR (100 MHz, CD2Cl2): δ 176.0, 153.5, 139.1, 128.7, 127.8, 127.4, 83.4, 47.7, 45.4, 38.5, 
32.9, 28.1, 26.9, 24.9. HRMS (ESI): Calcd for C18H26ClNO3Na [M+Na]: 362.1499; Found: 362.1508. 
IR (neat, cm
-1
): 1731, 1693, 1368, 1144, 700.   
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Synthesis of tert-Butyl Benzyl(5-(4-chloro-3,5-dimethylphenoxy)pentanoyl)carbamate (S13).  
 
  Step 1: In a nitrogen-filled glovebox, an oven-dried 30 mL re-sealable screw-cap test tube equipped 
with a Teflon-coated magnetic stir bar was charged with methyl 5-(4-chloro-3,5-
dimethylphenoxy)pentanoate
8
 (1 equiv, 3.25 mmol, 880 mg), benzylamine (1.5 equiv, 4.89 mmol, 0.60 
mL), zirconocene dichloride (15 mol %, 142 mg), and o-xylene solvent (12 mL).The reaction mixture 
was then stirred at 140 
o
C in a preheated oil bath overnight. After the reaction, the reaction mixture 
was dried in vacuo with the aid of a rotary evaporator, and the residue was washed with dilute HCl 
solution (~1 M, ~100 mL) and ethyl acetate (EtOAc, ~50 mL). The organic fraction was further 
washed with saturated NaOH solution (~20 mL), and finally saturated NaCl solution (~50 mL). The 
organic fraction was dried with MgSO4 powder and then concentrated in vacuo to obtain the residue as 
a secondary amide, N-benzyl-5-(4-chloro-3,5-dimethylphenoxy)pentanamide.  
  Step 2: All N-benzyl-5-(4-chloro-3,5-dimethylphenoxy)pentanamide prepared from step 1 was 
transferred into an oven-dried 250 mL round-bottom flask equipped with a Teflon-coated magnetic stir 
bar, and acetonitrile solvent (MeCN, 60 mL), 4-(N,N-dimethylamino)pyridine (DMAP, 10 mol %, 40 
mg), and di-tert-butyl dicarbonate (Boc2O, 1.3 equiv, 0.92 mL) were then added. The resulting 
mixture was stirred at room temperature overnight. After the reaction, the reaction mixture was dried 
in vacuo, and the crude product was washed with EtOAc, ~100 mL) and dilute HCl solution (~1 M, 
~100 mL). The organic fraction was further washed with saturated NaHCO3 solution (~50 mL) 
followed by saturated NaCl solution (~100 mL). The organic fraction was then concentrated in vacuo, 
and the residue was purified by flash chromatography with silica gel (without prior washing with 
Et3N/hexanes) using a mixture of hexanes/EtOAc (10:1) as an eluent to afford the title compound as a 
yellow amorphous solid (716 mg, 49%).  
  
1
H NMR (400 MHz, CDCl3): δ 7.30-7.20 (ovrlp, 5 H), 6.62 (s, 2 H), 4.88 (s, 2 H), 3.92 (t. J = 5.8 
Hz, 2 H), 2.99 (t. J = 7.2 Hz, 2 H), 2.32 (s, 6 H), 1.89-1.76 (ovrlp, 4 H), 1.40 (s, 9 H). 
13
C NMR (100 
MHz, CDCl3): δ 175.9, 156.9, 153.2, 138.4, 137.0, 128.4, 127.6, 127.2, 126.1, 114.6, 83.2, 67.9, 47.4, 
38.0, 28.8, 28.0, 21.9, 21.0. HRMS (ESI): Calcd for C25H32ClNO4Na [M+Na]: 468.1917; Found: 
468.1896. IR (neat, cm
-1
): 1732, 1693, 1371, 1323, 1149, 991, 861, 695. Mp: 50-52 
o
C. 
 
 
 
Synthesis of tert-Butyl (6-(4-Benzoylphenoxy)hexanoyl)(benzyl)carbamate (S14).  
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  Step 1: An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar 
was sequentially charged with dimethylformamide solvent (DMF, 250 mL), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl, 1.1 equiv, 28.6 mmol, 5.6 g), 1-hydroxybenzotriazole 
hydrate (HOBt.H2O, 1.1 equiv, 28.6 mmol, 4.4 g), triethylamine (Et3N, 1.1 equiv, 28.6 mmol, 3.9 
mL), benzylamine (1 equiv, 26 mmol, 2.8 g), and 6-chlorohexanoic acid (1 equiv, 26 mmol, 3.9 g). 
The reaction mixture was stirred at room temperature overnight. After the reaction, the reaction 
mixture was washed with water (~500 mL) and ethyl acetate (EtOAc, ~100 mL). The organic fraction 
was further washed with dilute HCl solution (~1 M, ~100 mL), followed by saturated NaOH solution 
(~30 mL), and finally saturated NaCl solution (~50 mL). The organic fraction was dried with MgSO4 
powder and then dried in vacuo with the aid of a rotary evaporator to obtain the residue as N-benzyl-6-
chlorohexanamide (61%, 22.1 mmol, 3.82 g).  
  Step 2: N-Benzyl-6-chlorohexanamide (1 equiv, 6 mmol, 1.44 g) prepared from step 1 was 
transferred into an oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir 
bar, and 4-hydroxybenzophenone (1.1 equiv, 6.6 mmol, 1.31 g), K2CO3 (1.5 equiv, 9 mmol, 1.24 g), 
and DMF solvent (100 mL) were then added. The reaction was then heated at 120 
o
C in a preheated oil 
bath overnight. After the reaction, the reaction mixture was washed with water (~500 mL) and ethyl 
acetate (EtOAc, ~100 mL). The organic fraction was further washed with saturated NaOH solution 
(~100 mL x 2) followed by saturated NaCl solution (~100 mL). The organic fraction was concentrated 
in vacuo, and the residue was purified by flash chromatography with silica gel (without prior washing 
with Et3N/hexanes) using a mixture of hexanes/EtOAc (5:1) as an eluent to afford 6-(4-
benzoylphenoxy)-N-benzylhexanamide.  
  Step 3: All 6-(4-benzoylphenoxy)-N-benzylhexanamide prepared from step 2 was transferred into an 
oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar, and 
acetonitrile solvent (MeCN, 100 mL), 4-(N,N-dimethylamino)pyridine (DMAP, 10 mol %, 73 mg), 
and di-tert-butyl dicarbonate (Boc2O, 1.1 equiv, 1.44 mL) were then added. The resulting mixture was 
stirred at room temperature overnight. After the reaction, the reaction mixture was concentrated in 
vacuo, and the crude product was washed with EtOAc, ~100 mL) and dilute HCl solution (~1 M, ~100 
mL). The organic fraction was further washed with saturated NaHCO3 solution (~50 mL) followed by 
saturated NaCl solution (~100 mL). The organic fraction was dried and concentrated in vacuo, and the 
residue was purified by flash chromatography with silica gel (without prior washing with 
Et3N/hexanes) using a mixture of hexanes/EtOAc (6:1) as an eluent to afford the title compound as a 
pale-yellow amorphous solid (2.15 g, 72%, yield based on 6-(4-benzoylphenoxy)-N-
benzylhexanamide, prepared from Step 2).  
  
1
H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.7 Hz, 2 H), 7.74 (d, J = 7.2 Hz, 2 H), 7.52 (t, J = 7.4 
Hz, 1 H), 7.43 (t, J = 7.3 Hz, 2 H), 7.30-7.18 (ovrlp, 5 H), 6.93 (d, J = 8.7 Hz, 2 H), 4.89 (s, 2 H), 4.01 
(t, J = 6.4 Hz, 2 H), 2.96 (t, J = 7.4 Hz, 2 H), 1.87-1.72 (ovrlp, 4 H), 1.53 (qu, J = 7.3 Hz, 2 H), 1.40 
(s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 195.3, 175.8, 162.7, 153.0, 138.3, 132.4, 131.7, 129.8, 129.6, 
128.2, 128.1, 127.4, 127.0, 114.0, 83.0, 67.9, 47.2, 38.1, 28.9, 27.8, 25.5, 24.8. HRMS (ESI): Calcd 
for C31H35NO5Na [M+Na]: 524.2413; Found: 524.2416. IR (neat, cm
-1
): 1718, 1694, 1649, 1600, 
1366, 1255, 1147, 995, 838, 740, 697. Mp: 61-63 
o
C. 
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Synthesis of 2-Fluoro-3-(4-nitrophenyl)pyridine (S15).  
 
In a nitrogen-filled glovebox, an oven-dried 30 mL re-sealable screw-cap test tube equipped with a 
Teflon-coated magnetic stir bar was charged with 1-iodo-4-nitrobenzene (1 equiv, 4 mmol, 996 mg), 
(2-fluoropyridin-3-yl)boronic acid (1.5 equiv, 6 mmol, 846 mg), Pd(OAc)2 (5 mol %, 45 mg), XPhos 
(10 mol%, 191 mg), K3PO4 (2 equiv, 8 mmol, 1.70 g), 1,4-dioxane solvent (10 mL), and deionized 
water (2 mL). The reaction mixture was then stirred at 100 
o
C in a preheated oil bath overnight. After 
the reaction, the reaction mixture was washed with water (~100 mL) and ethyl acetate (EtOAc, ~50 
mL). The aqueous fraction was further washed with EtOAc (2 x 20 mL). The combined organic 
fraction was dried with MgSO4 powder and then concentrated in vacuo with the aid of a rotary 
evaporator. The residue was purified by flash chromatography with silica gel (without prior washing 
with Et3N/hexanes) using a mixture of hexanes/EtOAc (5:1) as an eluent to afford the title compound 
as an off-white solid (572 mg, 66%). 
1
H NMR (400 MHz, CD2Cl2): δ 8.34 (d, J = 8.9 Hz, 2 H), 8.32-
8.30 (m, 1 H), 7.96-7.91 (m, 1 H), 7.76 (dd, JHH = 8.8 Hz, JHF = 1.5 Hz, 2 H),7.38-7.35 (m, 1 H). 
13
C 
NMR (100 MHz, CD2Cl2): δ 160.3 (d, JCF = 239.6 Hz), 148.2 (d, JCF = 14.9 Hz), 147.9, 140.9 (d, JCF 
= 3.7 Hz), 140.8 (d, JCF = 5.2 Hz), 129.9 (d, JCF = 3.3 Hz), 124.1, 122.3 (d, JCF = 4.5 Hz), 121.9 (d, JCF 
= 27.9 Hz). 
19
F NMR (376 MHz, CDCl3): δ -73.2. HRMS (ESI): Calcd for C11H8FN2O2 [M+H]: 
219.0564; Found: 219.0560. IR (neat, cm
-1
): 1607, 1512, 1447, 1398, 1345, 856, 842, 799, 762, 734, 
693. Mp: 183-185 
o
C.  
 
 
 
 
 
Synthesis of Amides via Nickel-Catalyzed Reductive Transamidation of Boc-activated 
Secondary Amides with Nitroarenes 
 
 
Nickel-Catalyzed Reductive Transamidation of Boc-activated Secondary Alkyl Amide with 
Nitroarene (General Procedure B). An oven-dried 30 mL re-sealable screw-cap test tube equipped 
with a Teflon-coated magnetic stir bar was sequentially charged with zinc powder (Zn, 5 equiv.), Boc-
activated amide (1 equiv.), nitroarene (1.5 equiv.), 1,10-phenanthroline (phen, 10-20 mol %), nickel(II) 
chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2, 10-20 mol %), N-methylpyrrolidone 
solvent (NMP, 0.5 M with respect to amide), and chlorotrimethylsilane (TMSCl, 1-1.5 equiv). The 
resulting mixture was stirred at a preheated oil bath for 16 h. After the reaction, the reaction mixture 
was cooled down to room temperature, and it was acidified with saturated NH4Cl solution (~5 mL) and 
then neutralized with saturated NaHCO3 solution (~10 mL). The crude product in the aqueous fraction 
was extracted with ethyl acetate (EtOAc, ~20 mL). The aqueous fraction was further washed with 
EtOAc (3 x ~10 mL). The combined organic fractions were concentrated in vacuo with the aid of a 
rotary evaporator. The residue was purified by preparative thin-layer chromatography (TLC) using a 
solvent mixture (hexanes and EtOAc) as an eluent to afford the purified amide product.  
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Nickel-Catalyzed Reductive Transamidation of Boc-activated Secondary Aryl Amide with 
Nitroarene (General Procedure C). An oven-dried 30 mL re-sealable screw-cap test tube equipped 
with a Teflon-coated magnetic stir bar was sequentially charged with manganese powder (Mn, 5 
equiv.), Boc-activated amide (1 equiv.), nitroarene (1.5 equiv.), 2,2′:6′,2′′-terpyridine (terpyridine, 7.5-
20 mol %), nickel(II) chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2, 7.5-20 mol %), 
N-methylpyrrolidone solvent (NMP, 0.5 M with respect to amide), and iodotrimethylsilane (TMSI, 1-2 
equiv). The resulting mixture was stirred at a preheated oil bath for 16 h. After the reaction, the reaction 
mixture was cooled down to room temperature, and it was acidified with saturated NH4Cl solution (~5 
mL) and then neutralized with saturated NaHCO3 solution (~10 mL). The crude product in the aqueous 
fraction was extracted with ethyl acetate (EtOAc, ~20 mL). The aqueous fraction was further washed 
with EtOAc (3 x ~10 mL). The combined organic fractions were concentrated in vacuo with the aid of a 
rotary evaporator. The residue was purified by preparative thin-layer chromatography (TLC) using a 
solvent mixture (hexanes and EtOAc) as an eluent to afford the purified amide product.  
 
 
 
 
 
N-(Quinolin-6-yl)decanamide (3a).
8
 Following the general procedure B, the title compound was 
prepared using tert-butyl benzyl(decanoyl)carbamate (1 equiv, 0.50 mmol, 181 mg), 6-nitroquinoline 
(1.5 equiv, 0.75 mmol, 131 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), phen (10 mol %, 9.0 mg), Zn (5 
equiv, 2.5 mmol, 164 mg), TMSCl (1.5 equiv, 0.75 mmol, 96 μL), and NMP (1.0 mL) at the reaction 
temperature of 100 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (2:1) 
as an eluent to afford the title compound as a pale brown amorphous solid (105 mg, 70%). 
1
H NMR 
(400 MHz, CDCl3): δ 8.81 (s, 1 H), 8.70 (s, 1 H), 8.45 (s, 1 H), 8.05 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 
9.0 Hz, 1 H), 7.61 (d, J = 9.1 Hz, 1 H), 7.34 (dd, J = 8.4 Hz, J = 4.3 Hz, 1 H), 2.42 (t, J = 7.6 Hz, 2 H), 
1.74 (qu, J = 7.7 Hz, 2 H), 1.36-1.17 (ovrlp, 12 H), 0.86 (t, J = 7.1 Hz, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 172.5, 149.2 145.4, 136.5, 136.1, 129.8, 129.0, 123.5, 121.7, 116.2, 37.8, 31.9, 29.50, 29.47, 
29.39, 29.3, 25.8, 22.7, 14.2. . IR (neat, cm
-1
): 3282, 1682, 1664, 1542, 1466, 1381, 1234, 834. 
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N-(Dibenzo[b,d]thiophen-3-yl)decanamide (3b). Following the general procedure B, the title 
compound was prepared using tert-butyl benzyl(decanoyl)carbamate (0.50 mmol, 181 mg), 3-
nitrodibenzo[b,d]thiophene (0.75 mmol, 172 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), phen (10 mol 
%, 9.0 mg), Zn (5 equiv, 2.5 mmol, 164 mg), TMSCl (1.5 equiv, 0.75 mmol, 96 μL), and NMP (1.0 
mL) at the reaction temperature of 100 
o
C.. The crude product was purified by preparative TLC using 
hexanes/EtOAc (8:1) as an eluent to afford the title compound as a brown amorphous solid (130 mg, 
74%). 
1
H NMR (400 MHz, CDCl3): δ 8.47 (s, 1 H), 8.00 (d, J = 7.7 Hz, 1 H), 7.81-7.76 (ovrlp, 2 H), 
7.66 (d, J = 8.5 Hz, 1 H), 7.42-7.32 (ovrlp, 3 H), 2.37 (t, J = 7.7 Hz, 2 H), 1.73 (qu, J = 7.0 Hz, 2 H), 
1.36-1.19 (ovrlp, 12 H), 0.87 (t, J = 6.2 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 172.1, 140.2, 136.2, 
135.4, 135.2, 134.9, 126.9, 124.4, 122.95, 122.85, 121.9, 119.8, 113.2, 37.9, 32.0, 29.59, 29.55, 29.5, 
29.4, 25.8, 22.8, 14.2. HRMS (ESI): Calcd for C22H28NOS [M+H]: 354.1900; Found: 354.1885. IR 
(neat, cm
-1
): 3284, 1652, 1572, 1520, 1469, 1413, 1223, 808, 756, 725. Mp: 136-138 
o
C.  
 
 
 
 
 
N-(4-(1H-Pyrazol-1-yl)phenyl)decanamide (3c).
8
 Following the general procedure B, the title 
compound was prepared using tert-butyl benzyl(decanoyl)carbamate (1 equiv, 0.50 mmol, 181 mg), 
1-(4-nitrophenyl)-1H-pyrazole (1.5 equiv, 0.75 mmol, 142 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), 
phen (10 mol %, 9.0 mg), Zn (5 equiv, 2.5 mmol, 164 mg), TMSCl (1.5 equiv, 0.75 mmol, 96 μL), 
and NMP (1.0 mL) at the reaction temperature of 100 
o
C. The crude product was purified by 
preparative TLC using hexanes/EtOAc (4:1) as an eluent to afford the title compound as an off-white 
amorphous solid (78 mg, 50%). 
1
H NMR (400 MHz, CDCl3): δ 7.87 (s, 1 H), 7.70 (s, 1 H), 7.65-7.56 
(ovrlp, 4 H), 7.47 (s, 1 H), 6.45 (s, 1 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J = 7.6 Hz, 2 H), 1.41-
1.20 (ovrlp, 12 H), 0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.7, 141.0, 136.6, 
136.5, 126.9, 120.7, 120.0, 107.6, 37.9, 32.0, 29.6, 29.5, 29.43, 29.41, 25.7, 22.8, 14.2. IR (neat, cm
-
1
): 3326, 1659, 1524, 1392, 1307, 1049, 937, 818.  
 
 
 
 
 
N-(2-Phenylbenzo[d]oxazol-5-yl)decanamide (3d).
8
 Following the general procedure B, the title 
 S20   
compound was prepared using tert-butyl benzyl(decanoyl)carbamate (1 equiv, 0.50 mmol, 181 mg), 5-
nitro-2-phenylbenzo[d]oxazole (1.5 equiv, 0.75 mmol, 180 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), 
phen (10 mol %, 9.0 mg), Zn (5 equiv, 2.5 mmol, 164 mg), TMSCl (1.5 equiv, 0.75 mmol, 96 μL), and 
NMP (1.0 mL) at the reaction temperature of 100 
o
C. The crude product was purified by preparative 
TLC using hexanes/EtOAc (8:1) as an eluent to afford the title compound as a pale brown amorphous 
solid (87 mg, 48%). 
1
H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 6.8 Hz, 2 H), 7.90 (s, 1 H), 7.77 (s, 1 
H), 7.56-7.45 (ovrlp, 5 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J = 7.5 Hz, 2 H), 1.36-1.24 (ovrlp, 12 H), 
0.86 (d, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.9, 163.9, 147.6, 142.5, 135.2, 131.7, 
129.0, 127.7, 127.1, 118.5, 111.7, 110.5, 37.8, 32.0, 29.6, 29.53, 29.46, 29.4, 25.8, 22.8, 14.2. IR 
(neat, cm
-1
): 3288, 1650, 1552, 1469, 1193, 1056, 775, 701.  
 
 
 
 
 
N-(1-Methyl-1H-indol-5-yl)decanamide (3e).
8
 Following the general procedure B, the title 
compound was prepared using tert-butyl benzyl(decanoyl)carbamate (0.35 mmol, 127 mg), 1-methyl-
5-nitro-1H-indole (0.525 mmol, 93 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), 
Zn (5 equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the 
reaction temperature of 100 
o
C. The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (8:1) as an eluent to afford the title compound as a deep brown amorphous solid (68 
mg, 65%). 
1
H NMR (400 MHz, CDCl3): δ 7.81 (s, 1 H), 7.28-7.24 (ovrlp, 2 H), 7.21 (s, 1 H), 7.03 (d, 
J = 3.1 Hz, 1 H), 6.42 (d, J = 3.1 Hz, 1 H), 3.76 (s, 3 H), 2.35 (t, J = 7.6 Hz, 2 H), 1.74 (qu, J = 7.6 Hz, 
2 H), 1.39-1.19 (ovrlp, 12 H), 0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.5, 134.3, 
130.3, 129.7, 128.6, 116.0, 112.9, 109.4, 101.1, 38.0, 33.1, 32.0, 29.62. 29.57, 29.5, 29.4, 26.0, 22.8, 
14.3. IR (neat, cm
-1
): 3289, 1652, 1539, 1302, 1244, 799, 711.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)decanamide (3f).
8
 
 
 
  (i) From tert-Butyl Decanoyl(methyl)carbamate (P-2, Figure 3 in maintext). Following the 
general procedure B, the title compound was prepared using tert-butyl decanoyl(methyl)carbamate 
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(0.35 mmol, 100 mg), 1-(tert-butyl)-4-nitrobenzene (0.525 mmol, 94 mg), Ni(glyme)Cl2 (10 mol %, 
7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 
mmol, 67 μL), and NMP (0.7 mL) at the reaction temperature of 120 oC.  The crude product was 
purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent to afford the title compound as 
a brown amorphous solid (66 mg, 62%). 
1
H NMR (400 MHz, CDCl3): δ 7.43 (d, J = 8.5 Hz, 2 H), 
7.32 (d, J = 8.5 Hz, 2 H), 7.27 (s, 1 H), 2.33 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J = 7.3 Hz, 2 H), 1.39-1.22 
(ovrlp, 21 H), 0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.5, 147.2, 135.5, 125.9, 
119.8, 37.9, 34.5, 32.0, 31.5, 29.6, 29.5, 29.4, 25.9, 22.8, 14.2. IR (neat, cm
-1
): 3301, 1659, 1604, 
1538, 1315, 833, 728.  
 
 
 
  (ii) From tert-Butyl (Cyclopropylmethyl)(decanoyl)carbamate (P-4, Figure 3 in maintext). 
Following the general procedure B, the title compound was prepared using tert-butyl 
(cyclopropylmethyl)(decanoyl)carbamate (0.35 mmol, 114 mg), 1-(tert-butyl)-4-nitrobenzene (0.525 
mmol, 94 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 equiv, 1.75 mmol, 
114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the reaction temperature of 
120 
o
C.  The crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent 
to afford the title compound as a brown amorphous solid (49 mg, 46%). Spectral and analytical data 
were identical to those reported for the same compound above. 
 
 
 
  (iii) From tert-Butyl Decanoyl(3-(methylthio)propyl)carbamate (P-6, Figure 3 in maintext). 
Following the general procedure B, the title compound was prepared using tert-butyl 
(cyclopropylmethyl)(decanoyl)carbamate (0.35 mmol, 126 mg), 1-(tert-butyl)-4-nitrobenzene (0.525 
mmol, 94 mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), phen (15 mol %, 9.5 mg), Zn (5 equiv, 1.75 
mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the reaction 
temperature of 120 
o
C.  The crude product was purified by preparative TLC using hexanes/EtOAc 
(10:1) as an eluent to afford the title compound as a brown amorphous solid (45 mg, 42%). Spectral 
and analytical data were identical to those reported for the same compound above.  
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  (iv) From tert-Butyl Decanoyl(2,2,2-trifluoroethyl)carbamate (P-7, Figure 3 in maintext). 
Following the general procedure B, the title compound was prepared using tert-butyl decanoyl(2,2,2-
trifluoroethyl)carbamate (0.35 mmol, 124 mg), 1-(tert-butyl)-4-nitrobenzene (0.525 mmol, 94 mg), 
Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 equiv, 1.75 mmol, 114.5 mg), 
TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the reaction temperature of 100 oC.  
The crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent to 
afford the title compound as a brown amorphous solid (84 mg, 81%). Spectral and analytical data 
were identical to those reported for the same compound above.  
 
 
 
 
 
N-(4-methoxyphenyl)decanamide (3g).
8
 Following the general procedure B, the title compound was 
prepared using tert-butyl decanoyl(phenethyl)carbamate (0.35 mmol, 132 mg), 4-nitroanisole (0.525 
mmol, 80 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 equiv, 1.75 mmol, 
114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the reaction temperature of 
120 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (5:1) as an eluent 
to afford the title compound as a brown amorphous solid (55 mg, 57%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.41 (d, J = 8.8 Hz, 2 H), 7.15 (s, 1 H), 6.84 (d, J = 8.7 Hz, 2 H), 3.78 (s, 3 H), 2.32 (t, J = 
7.6 Hz, 2 H), 1.71 (qu, J = 7.3 Hz, 2 H), 1.39-1.21 (ovrlp, 12 H), 0.88 (t, J = 6.9 Hz, 3 H). 
13
C NMR 
(100 MHz, CDCl3): δ 171.4, 156.5, 131.2, 121.9, 114.2, 55.6, 37.8, 32.0, 29.6, 29.5, 29.45, 29.42, 
25.9, 22.8, 14.2. 
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N-(4-(methylthio)phenyl)decanamide (3h).
8
 Following the general procedure B, the title compound 
was prepared using tert-butyl decanoyl(2-methoxyethyl)carbamate (0.35 mmol, 132 mg), 4-
nitrothioanisole (0.525 mmol, 89 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), 
Zn (5 equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at 
the reaction temperature of 120 
o
C.  The crude product was purified by preparative TLC using 
hexanes/EtOAc (7:1) as an eluent to afford the title compound as a brown amorphous solid (52 mg, 
50%). 
1
H NMR (400 MHz, CDCl3): δ 7.45 (d, J = 8.4 Hz, 2 H), 7.23 (d, J = 8.6 Hz, 2 H), 7.12 (s, 1 
H), 2.46 (s, 3 H), 2.34 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J = 7.3 Hz, 2 H), 1.38-1.23 (ovrlp, 12 H), 0.88 
(d, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.4, 135.8, 133.5, 128.2, 120.5, 38.0, 32.0, 
29.6, 29.5, 29.4, 25.8, 22.8, 16.9, 14.3. HRMS (ESI): Calcd for C17H28NOS [M+H]: 294.1891; 
Found: 294.1892. 
 
 
 
 
 
 
(E)-3-Phenyl-N-(4-styrylphenyl)propanamide (3i).
8
 Following the general procedure B, the title 
compound was prepared using tert-butyl benzyl(3-phenylpropanoyl)carbamate (0.35 mmol, 119 mg), 
(E)-1-nitro-4-styrylbenzene (0.525 mmol, 118 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol 
%, 6.3 mg), Zn (5 equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP 
(0.7 mL) at the reaction temperature of 100 
o
C.  The crude product was purified by preparative TLC 
using hexanes/EtOAc (5:1) as an eluent to afford the title compound as a pale brown amorphous solid 
(70 mg, 61%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.00 (s, 1 H), 7.62-7.52 (ovrlp, 6 H), 7.36 (t, J = 
7.6 Hz, 2 H), 7.31-7.23 (ovrlp, 5 H), 7.21-7.12 (ovrlp, 3 H), 2.92 (t, J = 7.8 Hz, 2 H), 2.64 (t, J = 7.6 
Hz, 2 H). 
13
C NMR (100 MHz, DMSO-d6): δ 170.4, 141.2, 138.8, 137.2, 131.9, 128.7, 128.34, 
128.26, 128.04, 127.4, 126.93, 126.90, 126.3, 126.0, 119.1, 38.0, 30.8. IR (neat, cm
-1
): 3278, 1648, 
1593, 1515, 1412, 1075, 967, 819, 690.  
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N-(p-Tolyl)undec-10-enamide (3j). Following the general procedure B, the title compound was 
prepared using tert-butyl benzyl(undec-10-enoyl)carbamate (0.30 mmol, 112 mg), 4-nitrotoluene 
(0.45 mmol, 62 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), phen (10 mol %, 5.4 mg), Zn (5 equiv, 1.5 
mmol, 98 mg), TMSCl (1.5 equiv, 0.45 mmol, 57 μL), and NMP (0.6 mL) at the reaction temperature 
of 100 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an 
eluent to afford the title compound as a pale brown amorphous solid (53 mg, 64%). 
1
H NMR (400 
MHz, CD2Cl2): δ 7.43 (s, 1 H), 7.39 (d, J = 8.2 Hz, 2 H), 7.11 (d, J = 8.2 Hz, 2 H), 5.88-5.78 (m, 1 
H), 5.02-4.97 (m, 1 H), 4.94-4.91 (m, 1 H), 2.32-2.28 (ovrlp, 5 H), 2.04 (q, J = 7.3 Hz, 2 H), 1.68 (d, 
J = 6.4 Hz, 2 H), 1.40-1.27 (ovrlp, 10 H). 
13
C NMR (100 MHz, CD2Cl2): δ 171.7, 139.7, 136.2, 
134.1, 129.7, 120.3, 114.3, 38.0, 34.2, 29.8, 29.7, 29.5, 29.4, 26.1, 21.0. HRMS (ESI): Calcd for 
C18H28NO [M+H]: 274.2171; Found: 274.2190. IR (neat, cm
-1
): 3303, 1660, 1594, 1523, 1404, 1251, 
1180, 911, 814. Mp: 68-70 
o
C. 
 
 
 
 
 
N-(p-Tolyl)cinnamamide (3k).
8
 Following the general procedure B, the title compound was prepared 
using tert-butyl benzyl(cinnamoyl)carbamate (0.30 mmol, 101 mg), 4-nitrotoluene (0.45 mmol, 62 
mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), phen (10 mol %, 5.4 mg), Zn (5 equiv, 1.5 mmol, 98 mg), 
TMSCl (1.5 equiv, 0.45 mmol, 57 μL), and NMP (0.6 mL) at the reaction temperature of 100 oC.  The 
crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent to afford the 
title compound as an off-white amorphous solid (38 mg, 53%). 
1
H NMR (400 MHz, CDCl3): δ 8.35 
(s, 1 H), 7.70 (d, J = 15.6 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 2 H), 7.37 (d, J = 7.1 Hz, 2 H), 7.31-7.22 
(ovrlp, 3 H), 7.07 (d, J = 7.9 Hz, 2 H), 6.65 (d, J = 15.5 Hz, 1 H), 2.27 (s, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 164.6, 142.0, 135.7, 134.8, 134.1, 129.8, 129.6, 128.8, 128.0, 121.4, 120.5, 21.0. IR (neat, 
cm
-1
): 3256, 1659, 1621, 1598, 1540, 1347, 985, 813.  
 
 
 
 
 
6-Chloro-N-(p-tolyl)hexanamide (3l). Following the general procedure B, the title compound was 
prepared using 6-chloro-N-(p-tolyl)hexanamide (1 equiv, 0.35 mmol, 119 mg), 4-nitrotoluene (1.5 
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equiv, 0.525 mmol, 94 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 
equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the 
reaction temperature of 100 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (40 
mg, 48%). 
1
H NMR (400 MHz, CD2Cl2): δ 7.38 (d, J = 8.1 Hz, 2 H), 7.24 (s, 1 H), 7.12 (d, J = 8.1 
Hz, 2 H), 3.56 (t, J = 6.6 Hz, 2 H), 2.35-2.30 (ovrlp, 5 H), 1.81 (qu, J = 7.3 Hz, 2 H), 1.72 (qu, J = 7.5 
Hz, 2 H), 1.50 (qu, J = 7.9 Hz, 2 H). 
13
C NMR (100 MHz, CD2Cl2): δ 171.1, 136.1, 134.2, 129.8, 
120.3, 45.5, 37.7, 32.8, 26.9, 25.2, 21.0. HRMS (ESI): Calcd for C13H19ClNO [M+H]: 240.1155; 
Found: 240,1167. IR (neat, cm
-1
): 3320, 1654, 1594, 1526, 1403, 1307, 814, 646. Mp: 83-85 
o
C.  
 
 
 
 
 
 
5-(4-Chloro-3,5-dimethylphenoxy)-N-(p-tolyl)pentanamide (3m).
21
 Following the general 
procedure B, the title compound was prepared using tert-butyl benzyl(5-(4-chloro-3,5-
dimethylphenoxy)pentanoyl)carbamate (1 equiv, 0.35 mmol, 156 mg), 4-nitrotoluene (1.5 equiv, 0.525 
mmol, 72 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), phen (10 mol %, 6.3 mg), Zn (5 equiv, 1.75 mmol, 
114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 mL) at the reaction temperature of 
100 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (8:1) as an eluent to 
afford the title compound as an off-white amorphous solid (73 mg, 60%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.70 (s, 1 H), 7.37 (d, J = 8.0 Hz, 2 H), 7.07 (d, J = 8.0 Hz, 2 H), 6.59 (s, 2 H), 3.89 (t, J = 
5.7 Hz, 2 H), 2.38 (t, J = 6.8 Hz, 2 H), 2.31 (s, 6 H), 2.28 (s, 3 H), 1.89-1.77 (ovrlp, 4 H). 
13
C NMR 
(100 MHz, CDCl3): δ 171.2, 156.8, 137.1, 135.5, 133.9, 129.5, 126.2, 120.2, 114.5, 67.7, 37.1, 28.7, 
22.5, 21.0, 20.9. IR (neat, cm
-1
): 3276, 1634, 1595, 1540, 1466, 1323, 1166, 1044, 819, 699, 669.  
 
 
 
 
 
6-(4-Benzoylphenoxy)-N-(4-(tert-butyl)phenyl)hexanamide (3n). Following the general procedure 
B, the title compound was prepared using tert-butyl (6-(4-
benzoylphenoxy)hexanoyl)(benzyl)carbamate (1 equiv, 0.35 mmol, 176 mg), 1-(tert-butyl)-4-
nitrotoluene (1.5 equiv, 0.525 mmol, 94 mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), phen (15 mol %, 
9.5 mg), Zn (5 equiv, 1.75 mmol, 114.5 mg), TMSCl (1.5 equiv, 0.525 mmol, 67 μL), and NMP (0.7 
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mL) at the reaction temperature of 130 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (5:1) as an eluent to afford the title compound as an off-white amorphous solid (55 
mg, 35%). 
1
H NMR (400 MHz, CDCl3): δ 7.81 (d, J = 8.0 Hz, 2 H), 7.75 (d, J = 7.6 Hz, 2 H), 7.57 (t, 
J = 7.4 Hz, 1 H), 7.49-7.42 (ovrlp, 4 H), 7.34-7.29 (ovrlp, 3 H), 6.93 (d, J = 8.1 Hz, 2 H), 4.04 (d, J = 
6.1 Hz, 2 H), 2.39 (t, J = 7.2 Hz, 2 H), 1.89-1.78 (ovrlp, 4 H), 1.57 (qu, J = 6.9 Hz, 2 H), 1.29 (s, 9 
H). 
13
C NMR (100 MHz, CDCl3): δ 195.8, 171.1, 162.9, 147.4, 138.4, 135.4, 132.7, 132.0, 130.1, 
129.9, 128.3, 125.9, 119.7, 114.1, 68.0, 37.6, 34.5, 31.5, 29.0, 25.8, 25.4. HRMS (ESI): Calcd for 
C29H33NO3Na [M+Na]: 466.2353; Found: 466.2345. IR (neat, cm
-1
): 3361, 1675, 1635, 1598, 1527, 
1253, 1021, 837, 739, 698. Mp: 121-123 
o
C. 
 
 
 
 
 
N-(2,5-dimethoxyphenyl)decanamide (3o). Following the general procedure B, the title compound 
was prepared using tert-butyl benzyl(decanoyl)carbamate (1 equiv, 0.30 mmol, 108 mg), 2,5-
dimethoxynitrotoluene (1.5 equiv, 0.45 mmol, 82 mg), Ni(glyme)Cl2 (15 mol %, 9.9 mg), phen (15 
mol %, 8.1 mg), Zn (5 equiv, 1.5 mmol, 98 mg), TMSCl (1.5 equiv, 0.45 mmol, 57 μL), and NMP 
(0.6 mL) at the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC 
using hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous 
solid (42 mg, 45%). 
1
H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 2.6 Hz, 1 H), 7.77 (s, 1 H), 6.78 (d, J 
= 8.9 Hz, 1 H), 6.56 (dd, J = 8.9 Hz, J = 3.0 Hz, 1 H), 3.84 (s, 3 H), 3.78 (s, 3 H), 2.38 (t, J = 7.5 Hz, 
2 H), 1.73 (qu, J = 7.6 Hz, 2 H), 1.41-1.26 (ovrlp, 12 H), 0.88 (d, J = 6.9 Hz, 3 H). 
13
C NMR (100 
MHz, CDCl3): δ 171.5, 154.0, 142.0, 128.6, 110.8, 108.6, 105.9, 56.3, 55.9, 38.3, 32.0, 29.6, 29.5, 
29.42, 29.38, 25.7, 22.8, 14.2. HRMS (ESI): Calcd for C18H29NO3Na [M+Na]: 330.2045; Found: 
330.2047. IR (neat, cm
-1
): 3259, 1660, 1595, 1537, 1493, 1223, 1038, 803, 721.  Mp: 65-67 
o
C.  
 
 
 
 
 
N-(3-Fluoro-4-methylphenyl)benzamide (4a). Following the general procedure C, the title 
compound was prepared using tert-butyl benzoyl(benzyl)carbamate (0.30 mmol, 93 mg), 2-fluoro-4-
nitrotoluene (0.45 mmol, 70 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), terpyridine (10 mol %, 7.0 mg), 
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Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 mL) at the 
reaction temperature of 80 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (50 
mg, 73%). 
1
H NMR (400 MHz, CD2Cl2): δ 7.98 (s, 1 H), 7.85 (d, J = 7.4 Hz, 2 H), 7.59-7.55 (ovrlp, 
2 H), 7.49 (t, J = 7.2 Hz, 2 H), 7.20-7.14 (ovrlp, 2 H), 2.25 (s, 3 H). 
13
C NMR (100 MHz, CD2Cl2): δ 
165.9, 161.6 (d, 
1
JCF = 241.4 Hz), 137.8 (d, 
3
JCF = 10.7 Hz), 135.3, 132.3, 131.8 (d, 
3
JCF = 6.4 Hz), 
129.2, 127.4, 121.1 (d, 
2
JCF = 17.4 Hz), 115.8 (d, 
4
JCF = 3.4 Hz), 107.8 (d, 
2
JCF = 27.3 Hz), 14.2 (d, 
3
JCF = 3.3 Hz). 
19
F NMR (376 MHz, CDCl3): δ -118.4. HRMS (ESI): Calcd for C14H13FNO [M+H]: 
230.0981; Found: 230.0984. IR (neat, cm
-1
): 3319, 1653, 1597, 1508, 1413, 1267, 858, 813. Mp: 117-
119 
o
C. 
 
 
 
 
 
N-(3-Chloro-4-methoxyphenyl)benzamide (4b). Following the general procedure C, the title 
compound was prepared using tert-butyl benzoyl(benzyl)carbamate (0.30 mmol, 93 mg), 2-chloro-4-
nitroanisole (0.45 mmol, 84 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), terpyridine (10 mol %, 7.0 mg), 
Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 mL) at the 
reaction temperature of 80 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (5:1) as an eluent to afford the title compound as an off-white amorphous solid (63 
mg, 80%). 
1
H NMR (400 MHz, CD2Cl2): δ 8.00 (s, 1 H), 7.84 (d, J = 7.0 Hz, 2 H), 7.73 (s, 1 H), 7.55 
(d, J = 6.9 Hz, 1 H), 7.50-7.44 (ovrlp, 3 H), 6.92 (d, J = 8.8 Hz, 1 H), 3.88 (s, 3 H). 
13
C NMR (100 
MHz, CD2Cl2): δ 166.0, 152.5, 135.1, 132.2, 132.1, 129.1, 127.4, 123.2, 122.7, 120.6, 112.7, 56.7. 
HRMS (ESI): Calcd for C14H13ClNO2 [M+H]: 262.0645; Found: 262.0641. IR (neat, cm
-1
): 3303, 
1648, 1515, 1500, 1403, 1253, 1219, 1059, 1019, 811, 691. Mp: 153-155 
o
C.  
 
 
 
 
 
N-(3-Bromo-4-methylphenyl)benzamide (4c). Following the general procedure C, the title 
compound was prepared using tert-butyl benzoyl(benzyl)carbamate (0.30 mmol, 93 mg), 2-bromo-4-
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nitrotoluene (0.45 mmol, 97 mg), Ni(glyme)Cl2 (7.5 mol %, 5.0 mg), terpyridine (7.5 mol %, 5.3 mg), 
Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 mL) at the 
reaction temperature of 80 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (61 
mg, 69%). 
1
H NMR (400 MHz, CD2Cl2): δ 8.15 (s, 1 H), 7.93 (d, J = 1.5 Hz, 1 H), 7.84 (d, J = 7.5 
Hz, 2 H), 7.54 (d, J = 1.8 Hz, 1 H), 7.47-7.44 (ovrlp, 3 H), 7.20 (d, J = 8.2 Hz, 1 H), 2.37 (s, 3 H). 
13
C 
NMR (100 MHz, CD2Cl2): δ 166.1, 137.4, 135.1, 134.3, 132.3, 131.1, 129.1, 127.4, 125.0, 124.4, 
119.8, 22.4. HRMS (ESI): Calcd for C14H13BrNO [M+H]: 290.0189; Found: 290.0181. IR (neat, cm
-
1
): 3282, 1644, 1578, 1507, 1491, 1307, 1255, 1035, 858, 812, 690. 670. Mp: 135-137 
o
C.  
 
 
 
 
 
N-(4-(2-Fluoropyridin-3-yl)phenyl)benzamide (4d). Following the general procedure C, the title 
compound was prepared using tert-butyl benzoyl(benzyl)carbamate (0.30 mmol, 93 mg), 2-fluoro-3-
(4-nitrophenyl)pyridine (0.45 mmol, 98 mg), Ni(glyme)Cl2 (15 mol %, 9.9 mg), terpyridine (15 mol 
%, 10.5 mg), Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 mL) 
at the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (3:1) as an eluent to afford the title compound as an off-white amorphous solid (70 
mg, 80%). 
1
H NMR (400 MHz, CD2Cl2): δ 8.17 (s, 1 H), 8.01 (s, 1 H), 7.94-7.87 (ovrlp, 3 H), 7.79 
(d, J = 7.6 Hz, 2 H), 7.62-7.58 (ovrlp, 3 H), 7.53 (t, J = 6.4 Hz, 2 H), 7.31 (t, J = 6.5 Hz, 1 H). 
13
C 
NMR (100 MHz, DMSO-d6): δ 165.9, 159.7 (d, JCF = 235.6 Hz), 146.1 (d, JCF = 14.8 Hz), 141.1 (d, 
JCF = 4.2 Hz), 139.5, 134.8, 131.8, 129.2 (d, JCF = 3.0 Hz), 128.5, 127.8, 122.8 (d, JCF = 4.0 Hz), 
122.7 (d, JCF = 27.7 Hz), 120.5, 118.4. 
19
F NMR (376 MHz, CDCl3): δ -74.1. HRMS (ESI): Calcd 
for C18H14FN2O [M+H]: 293.1090; Found: 293.1104. IR (neat, cm
-1
): 3368, 1660, 1591, 1518, 1429, 
1395, 1317, 1238, 832, 792, 713. Mp: 193-195 
o
C. 
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N-(4-(tert-Butyl)phenyl)-4-fluorobenzamide (4e).
8
 Following the general procedure C, the title 
compound was prepared using tert-butyl benzyl(4-fluorobenzoyl)carbamate
  
(0.30 mmol, 99 mg), 1-
(tert-butyl)-4-nitrobenzene (0.45 mmol, 81 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), terpyridine (10 
mol %, 7.0 mg), Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 
mL) at the reaction temperature of 80 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (62 
mg, 76%). 
1
H NMR (400 MHz, CDCl3): δ 7.95 (s, 1 H), 7.85 (dd, 
3
JHH = 8.1 Hz, 
4
JCF = 5.6 Hz, 2 H), 
7.53 (d, J = 8.4 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 7.10 (dd, 
3
JHH = 8.1 Hz, 
3
JCF = 8.1 Hz, 2 H), 1.32 
(s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 164.93 (d, 
1
JCF = 250.9 Hz), 164.91, 147.9, 135.3, 131.3 (d, 
4
JCF = 3.1 Hz), 129.6 (d, 
3
JCF = 8.9 Hz), 126.0, 120.4, 115.9 (d, 
2
JCF = 21.8 Hz), 34.6, 31.5. IR (neat, 
cm
-1
): 3312, 1644, 1601, 1503, 1330, 1226, 1160, 840, 758, 665.  
 
 
 
 
 
4-(tert-Butyl)-N-(4-(methylsulfonyl)phenyl)benzamide (4f).
8
 Following the general procedure C, the 
title compound was prepared using tert-butyl benzyl(4-(tert-butyl)benzoyl)carbamate (1 equiv, 0.35 
mmol, 129 mg), 1-(methylsulfonyl)-4-nitrobenzene (1.5 equiv, 0.525 mmol, 106 mg), Ni(glyme)Cl2 
(15 mol %, 11.6 mg), terpyridine (15 mol %, 12.2 mg), Mn (5 equiv, 1.75 mmol, 96 mg), TMSI (1.5 
equiv, 0.525 mmol, 75 μL), and NMP (0.7 mL) at the reaction temperature of 130 oC. The crude 
product was purified by preparative TLC using hexanes/EtOAc (4:1) as an eluent to afford the title 
compound as a pale brown amorphous solid (57 mg, 52%). 
1
H NMR (400 MHz, CDCl3): δ 8.60 (s, 1 
H), 7.88-7.80 (ovrlp, 6 H), 7.47 (d, J = 8.2 Hz, 2 H), 3.02 (s, 3 H), 1.33 (s, 9 H). 
13
C NMR (100 MHz, 
CDCl3): δ 166.3, 156.2, 143.4, 135.1, 131.2, 128.6, 127.3, 125.9, 120.3, 44.8, 35.1, 31.2. IR (neat, cm
-
1
): 3360, 1675, 1590, 1505, 1298, 1141, 964, 831, 768.  
 
 
 
 
 
N-(3-(Trifluoromethyl)phenyl)-2-naphthamide (4g).
8
 Following the general procedure C, the title 
compound was prepared using tert-butyl (2-naphthoyl)(benzyl)carbamate (0.30 mmol, 108 mg), 3-
nitrobenzotrlfluoride (0.45 mmol, 86 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), terpyridine (10 mol %, 
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7.0 mg), Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), and NMP (0.6 mL) at 
the reaction temperature of 80 
o
C. The crude product was purified by preparative TLC using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as an off-white amorphous solid (62 
mg, 66%). 
1
H NMR (400 MHz, CDCl3): δ 8.33 (s, 1 H), 8.27 (s, 1 H), 7.98 (s, 1 H), 7.93-7.85 (ovrlp, 
5 H), 7.60-7.52 (ovrlp, 2 H), 7.47 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.8 Hz, 1 H). 
13
C NMR (100 MHz, 
CDCl3): δ 138.7, 135.1, 132.7, 131.7, 131.6 (q, 
2
JCF = 32.3 Hz), 129.8, 129.1, 129.0, 128.3, 128.1, 
128.0, 127.8, 127.2 (q, 
1
JCF = 270.6 Hz), 123.52, 123.46 (q, 
4
JCF = 0.8 Hz), 121.2 (q, 
3
JCF = 3.8 Hz), 
117.1 (q, 
3
JCF = 4.0 Hz). 
19
F NMR (376 MHz, CDCl3): δ -65.9. IR (neat, cm
-1
): 3261, 1649, 1552, 
1446, 1325, 1165, 1108, 1068, 800, 778.  
 
 
 
 
 
N-(4-(tert-Butyl)phenyl)-4-(trifluoromethyl)benzamide (4h).
21
 Following the general procedure C, 
the title compound was prepared using tert-butyl isobutyl(4-(trifluoromethyl)benzoyl)carbamate (0.30 
mmol, 104 mg), 1-(tert-butyl)-4-nitrobenzene (0.45 mmol, 81 mg), Ni(glyme)Cl2 (10 mol %, 6.6 mg), 
terpyridine (10 mol %, 7.0 mg), Mn (5 equiv, 1.5 mmol, 83 mg), TMSI (1 equiv, 0.30 mmol, 43 μL), 
and NMP (0.6 mL) at the reaction temperature of 80 
o
C. The crude product was purified by 
preparative TLC using hexanes/EtOAc (10:1) as an eluent to afford the title compound as a pale 
brown amorphous solid (73 mg, 76%). 
1
H NMR (400 MHz, CDCl3): δ 8.69 (s, 1 H), 7.85 (d, J = 7.9 
Hz, 2 H), 7.55-7.52 (ovrlp, 4 H), 7.31 (d, J = 8.4 Hz, 2 H), 1.30 (s, 9 H). 
13
C NMR (100 MHz, 
CDCl3): δ 165.2, 148.2, 138.3, 135.1, 133.3 (q, 
2
JCF = 32.5 Hz), 127.8, 125.9, 125.6 (q, 
3
JCF = 3.7 
Hz), 123.7 (q, 
1
JCF = 270.9 Hz), 120.8, 34.5, 31.4. 
19
F NMR (376 MHz, CDCl3): δ -66.1. IR (neat, 
cm
-1
): 3313, 1655, 1529, 1324, 1164, 1119, 1065, 1016, 831.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)benzamide (4i).
9 
 
 
  (i) From tert-butyl benzoyl(propyl)carbamate (P-9 of Figure 4 in maintext). Following the 
general procedure C, the title compound was prepared using tert-butyl benzoyl(propyl)carbamate (1 
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equiv, 0.35 mmol, 92 mg), 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.525 mmol, 94 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), terpyridine (15 mol %, 12.2 mg), Mn (5 equiv, 1.75 mmol, 96 
mg), TMSI (1 equiv, 0.70 mmol, 50 μL), and NMP (0.7 mL) at the reaction temperature of 120 oC. 
The crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent to 
afford the title compound as a pale brown amorphous solid (60 mg, 68%).
 1
H NMR (400 MHz, 
CD2Cl2): δ 7.96 (s, 1 H), 7.86 (d, J = 7.2 Hz, 2 H), 7.58-7.53 (ovrlp, 3 H), 7.49 (t, J = 7.1 Hz, 2 H), 
7.40 (d, J = 8.6 Hz, 2 H), 1.33 (s, 9 H). 
13
C NMR (100 MHz, CD2Cl2): δ 165.9, 147.9, 135.9, 135.6, 
132.1, 129.1, 127.3, 126.2, 120.4, 34.7, 31.5.  IR (neat, cm
-1
): 3310, 1649, 1521, 1488, 1287, 820, 
709.  
 
 
 
  (ii) From tert-butyl benzoyl(hexyl)carbamate (P-10 of Figure 4 in maintext). Following the 
general procedure C, the title compound was prepared using tert-butyl benzoyl(hexyl)carbamate (1 
equiv, 0.35 mmol, 107 mg), 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.525 mmol, 94 mg), 
Ni(glyme)Cl2 (10 mol %, 7.7 mg), terpyridine (10 mol %, 8.1 mg), Mn (5 equiv, 1.75 mmol, 96 mg), 
TMSI (1 equiv, 0.70 mmol, 50 μL), and NMP (0.7 mL) at the reaction temperature of 120 oC. The 
crude product was purified by preparative TLC using hexanes/EtOAc (10:1) as an eluent to afford the 
title compound as a pale brown amorphous solid (58 mg, 66%). Spectral and analytical data were 
identical to those reported for the same compound above.  
 
 
 
 
 
N-(4-(9H-carbazol-9-yl)phenyl)-4-methylbenzamide (4j).
8 
Following the general procedure C, the 
title compound was prepared using tert-butyl benzyl(4-methylbenzoyl)carbamate (1 equiv, 0.35 mmol, 
114 mg), 9-(4-nitrophenyl)-9H-carbazole (1.5 equiv, 0.525 mmol, 151 mg), Ni(glyme)Cl2 (15 mol %, 
11.6 mg), terpyridine (15 mol %, 12.2 mg), Mn (5 equiv, 1.75 mmol, 96 mg), TMSI (1.5 equiv, 0.525 
mmol, 75 μL), and NMP (0.7 mL) at the reaction temperature of 120 oC. The crude product was 
purified by preparative TLC using hexanes/EtOAc (8:1) as an eluent to afford the title compound as a 
pale brown amorphous solid (67 mg, 51%). 
1
H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 7.8 Hz, 2 H), 
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7.98 (s, 1 H), 7.88 (d, J = 8.8 Hz, 2 H), 7.83 (d, J = 8.2 Hz, 2 H), 7.55 (d, J = 8.7 Hz, 2 H), 7.43-7.38 
(ovrlp, 4 H), 7.32 (d, J = 8.2 Hz, 2 H), 7.30-7.26 (m, 2 H), 2.45 (s, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 166.1, 142.8, 141.1, 137.4, 133.8, 131.9, 129.6, 127.9, 127.3, 126.1, 123.4, 121.7, 120.4, 
120.0, 109.8, 21.6. IR (neat, cm
-1
): 3258, 1647, 1517, 1449, 1314, 1225, 740, 717.  
 
 
 
 
N-(2,4-dimethylphenyl)-4-methoxybenzamide (4k). Following the general procedure C, the title 
compound was prepared using tert-butyl benzyl(4-methoxybenzoyl)carbamate (1 equiv, 0.35 mmol, 
119 mg), 2,4-dimethylnitrobenzene (1.5 equiv, 0.525 mmol, 82 mg), Ni(glyme)Cl2 (15 mol %, 11.6 
mg), terpyridine (15 mol %, 12.2 mg), Mn (5 equiv, 1.75 mmol, 96 mg), TMSI (1.5 equiv, 0.525 
mmol, 75 μL), and NMP (0.7 mL) at the reaction temperature of 120 oC. The crude product was 
purified by preparative TLC using hexanes/EtOAc (5:1) as an eluent to afford the title compound as a 
pale brown amorphous solid (45 mg, 50%). 
1
H NMR (400 MHz, CD2Cl2): δ 7.84 (d, J = 8.8 Hz, 2 
H), 7.66-7.60 (ovrlp, 2 H), 7.06 (s, 1 H), 7.04 (d, J = 8.2 Hz, 1 H), 6.98 (d, J = 8.8 Hz, 2 H), 3.87 (s, 3 
H), 2.32 (s, 3 H), 2.27 (s, 3 H). 
13
C NMR (100 MHz, CD2Cl2): δ 165.4, 162.8, 135.5, 133.9, 131.5, 
130.8, 129.3, 127.6, 127.5, 124.1, 114.2, 55.9, 21.0, 18.0. HRMS (ESI): Calcd for C16H18NO2 
[M+H]: 256.1338; Found: 256.1353. IR (neat, cm
-1
): 3270, 1638, 1606, 1509, 1301, 1253, 1176, 
1025, 843, 682. Mp: 152-154 
o
C.  
 
 
 
 
N-(3-methoxy-4-methylphenyl)benzamide (4l).
8
 Following the general procedure C, the title 
compound was prepared using N-phenylbenzamide (1 equiv, 0.35 mmol, 69 mg), 2-methoxy-1-
methyl-4-nitrobenzene (1.5 equiv, 0.525 mmol, 88 mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), 
terpyridine (15 mol %, 12.2 mg), Mn (5 equiv, 1.75 mmol, 96 mg), TMSI (2 equiv, 0.70 mmol, 100 
μL), and NMP (0.7 mL) at the reaction temperature of 140 oC. The crude product was purified by 
preparative TLC using hexanes/EtOAc (8:1) as an inseparable mixture of title compound and starting 
material (N-phenylbenzamide). The yield of title compound was calculated by comparing the ratio of 
title compound and starting material by 
1
H NMR spectroscopy of the separated product (42 mg, 49%).   
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